LATIGO BIOTHERAPEUTICS (LTGO)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$14.04-3.64%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
QuarterlyIQ Insights · LTGO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
CEO — Nima Farzan: The CEO is being replaced by a named successor (Todd Smith) with a structured transition and separation agreement, indicating an orderly succession rather than a sudden loss or termination for cause.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.